Drugs / NTX-301
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04167917 | Jan 2021 → Apr 2025 | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04851834 | Aug 2021 → Nov 2022 | malignant glioma, urothelial carcinoma | Xennials Therapeutics Australia Pty Ltd | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NTX-301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04167917 ↗ |
| Action | Inhibit | “NTX-301 is a DNMT1 inhibitor.” NCT04167917 ↗ |
| Modality | Other / unclassified | “oral hypomethylating agent” NCT04167917 ↗ |
| Route | Oral | “The drug is an oral drug” NCT04167917 ↗ |
| Target | DNMT1 | “NTX-301 is a DNMT1 inhibitor.” NCT04167917 ↗ |